Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson’s Disease

Table 1

Demographic and nonmotor features of Parkinson’s disease (PD) patients and control subjects.

	PD patients ()	Control subjects ()	value
Gender (female/male)	13/27	6/19	0.58^a
Age in years (mean ± SD)	68.71 ± 10.07	65.23 ± 8.75	0.20^b
Body mass index in Kg/m^2 (mean ± SD)	26.02 ± 3.73	27.64 ± 3.71	0.09^c
Educational level in years (mean ± SD)	4.72 ± 2.87	6.72 ± 5.37	0.16^b
MMSE [mean ± SD (median)]	24.00 ± 3.99 (25)	27.00 ± 3.57 (29)	0.001^b
FAB [mean ± SD (median)]	11.49 ± 2.99 (12)	12.32 ± 3.67 (13)	0.32^c
Conceptualization	1.23 ± 1.01 (1)	1.64 ± 1.11 (2)	0.12^b
Mental flexibility	1.82 ± 1.10 (2)	2.08 ± 1.04 (2)	0.34^b
Programming	1.74 ± 0.91 (2)	2.24 ± 0.83 (2)	0.04^b
Sensitivity to interference	2.26 ± 0.94 (3)	1.84 ± 1.25 (2)	0.21^b
Inhibitory control	1.41 ± 0.88 (1)	1.52 ± 1.09 (1)	0.73^b
Environmental autonomy	3.00 ± 0.00 (3)	3.00 ± 0.00 (3)	1.00^b
BDI [mean ± SD (median)]	8.64 ± 7.58 (6)	2.76 ± 3.35 (1)	<0.001^b
Medication in use (frequency in %)
Antihypertensive (%)	55.00	48.00	0.62^a
Antidiabetic (%)	10.00	20.00	0.29^a
Hypolipidemic (%)	10.00	24.00	0.17^a
Levothyroxine (%)	10.00	4.00	0.64^a
Antidepressants	20.00	12.00	0.51^a

BDI: Beck Depression Inventory; FAB: Frontal Assessment Battery; MMSE: Mini-Mental State Examination; PD: Parkinson’s disease; SD: standard deviation.
^aFisher’s exact test; ^bMann-Whitney test; ^cStudent’s test.